In a canine model we investigated the toxicity and pharmacokinetics of a water soluble busulfan preparation. Busulfan was dissolved in dimethylsulfoxide (DMSO) and administered either orally or intravenously in a single dose of 1 mg/ kg. The application in either preparation was well tolerated. In seven dogs, peak levels in the range of 730 ng/mL to 1,000 ng/mL were measured after intravenous injection with an area under curve (AUC) of 75 ng -h/kg * mL to 146 ng h/ kg-mL. It was of note that even the oral administration of the same busulfan preparation resulted in AUC values RAL HIGH-DOSE BUSULFAN is widely used as myeloablative and antileukemic treatment before bone marrow transplantation (BMT).' In randomized studies comparing busulfan with non-busulfan-containing regimens, comparable overall efficacy was ~h o w n '~~ in all but one study in patients with acute myelogenous leukemia? However, the use of busulfan is not without problems. For example, hepatic veno-occlusive disease, the most common and often lifethreatening preparative-regimen-related toxicity after BMT, is conceivably correlated with higher exposure to b~sulfan.~ At the same time, reduced busulfan concentrations might be associated with an increased risk of graft rejection and possibly recurrence of leukemia. Also highly variable busulfan concentration profiles have been observed by several other authors,6-8 presumably caused by variable gastrointestinal absorption rates. For this reason one prospective nonrandomized study was performed with exposure (area under curve [AUC]) -guided dose reduction' aimed at achieving safer or more efficacious plasma busulfan concentrations. Another strategy to circumvent these pharmacokinetic problems is the development of an intravenous formulation of busulfan. The aim of the present study was to use a water-soluble busulfan solution in an animal model with the objective of determining acute toxicity and in addition, to characterize pharmacokinetic parameters of intravenous and oral applications.
RAL HIGH-DOSE BUSULFAN is widely used as myeloablative and antileukemic treatment before bone marrow transplantation (BMT).' In randomized studies comparing busulfan with non-busulfan-containing regimens, comparable overall efficacy was ~h o w n '~~ in all but one study in patients with acute myelogenous leukemia? However, the use of busulfan is not without problems. For example, hepatic veno-occlusive disease, the most common and often lifethreatening preparative-regimen-related toxicity after BMT, is conceivably correlated with higher exposure to b~sulfan.~ At the same time, reduced busulfan concentrations might be associated with an increased risk of graft rejection and possibly recurrence of leukemia. Also highly variable busulfan concentration profiles have been observed by several other authors,6-8 presumably caused by variable gastrointestinal absorption rates. For this reason one prospective nonrandomized study was performed with exposure (area under curve [AUC]) -guided dose reduction' aimed at achieving safer or more efficacious plasma busulfan concentrations. Another strategy to circumvent these pharmacokinetic problems is the development of an intravenous formulation of busulfan. The aim of the present study was to use a water-soluble busulfan solution in an animal model with the objective of determining acute toxicity and in addition, to characterize pharmacokinetic parameters of intravenous and oral applications.
MATERIALS AND METHODS

Dogs.
Seven beagle dogs 12 to 20 months old and weighing 7.3 to 16.9 kg were included in a pharmacokinetic study. Dogs were housed and provided with commercial chow and drinking water ad libitum as described"; the kennel facilities and animal care were in accordance with the guidelines enunciated by the National Academy of Sciences. The experimental protocol was approved by the Institutional Animal Care and Users Committee of the Fred Hutchinson Cancer Research Center.
For 12 hours before each experiment, dogs received no food, but had free access to drinking water. No other medications were given concomitantly. Each dog received a dose of 1 mgkg of busulfan intravenously as single dose. In addition, the solution was given orally to five dogs at an interval of 14 days. To determine bioavailability of a conventional preparation of busulfan, three dogs received the same dose in the form of oral tablets (Myleran, Wellcome, Burgwedel, Germany) at an interval of 14 days before or after administration of water-soluble busulfan.
Toxicity was assessed by daily clinical examination and twice weekly determination of peripheral blood leukocytes, differential blood cell and platelet counts as well as hematocrit.
Drug preparations. Two-milligram tablets of conventional busulfan formulation (Myleran, Wellcome, Burgwedel, Germany) were used as an oral control preparation. The oral liquid formulation was prepared according to the following procedure: the required amount of tablets was ground and dissolved in 1 mL dimethylsulfoxide (DMSO; Aldrich Chemical CO, Milwaukee, WI). The required amount of busulfan-DMSO-solution was diluted in 50 mL of 0.9% sodium chloride and given orally. The intravenous formulation was prepared by the following procedure: 40 mg of busulfan powder (Aldrich Chemical CO, Steinheim, Germany) were dissolved in 1 mL DMSO, the required amount was filtered (0.2 pm PTFE filter; Lida Manufacturing Corp. Kenosha, WI) into 50 mL 0.9% sodium chloride and the solution was administered via an intravenous cannula over 2 minutes. The measurements of busulfan concentration in aliquots showed no loss during the preparation steps. The halflife of busulfan degradation in the administered solution at 20°C is 81 hours.
Blood sampling. Blood samples were obtained before and .25, .5, .75, 1, 1.5, 2, 3, 4, 5, 6, 24, and 48 hours after dosing. The samples were immediately placed on ice and centrifuged at 4,OOOg at 4°C. Plasma was separated and stored at -20°C until analysis. Analysis. Busulphan in plasma was assayed using the previously described high-performance liquid chromatography (HPLC) method with minor modifications.'' In brief, solid-phase extraction on Bond Elut TM C8 cartridges was used for sample clean-up. In a precolumn derivatization, the extracted busulfan was converted into 1.4-diiodobutane. The separation of 1,4-diiodobutane was achieved with an isocratic HPLC system using a guard column of 5 pm LiChrosorb CN (E. Merck, Darmstadt, Germany) and a Gromsil 100-CN analytical column (M. Grom, Herrenberg, Germany). The solvent system was water-acetonitrile (78:22, vol/vol) at a flow-rate of 1 mL/min. 
RESULTS
The application of busulfan in either preparation was well tolerated. No clinical side effects or significant changes in blood cell values were detected with the given dose of 1 Pharmacokinetic results are summarized in Table 1 . After bolus intravenous injection of busulfan, peak levels in the range of 730 ng/mL to 1,010 ng/mL were measured (Fig 1) . m g h . The AUC ranged from 78 ng * h k g -mL to 146 ng * h k g mL. Both compartmental and noncompartmental fitting showed elimination half-lives between 0.6 and 1.5 hours (median, 0.6 hours). Volume of distribution ranged from 0.8 to 1.4 L/kg (median, 1 Lkg).
In live of the seven dogs, the same busulfan solution used intravenously was also administered orally. Peak plasma levels occurred 0.5 to 1.5 hours after dosing and ranged from 540 ng/mL to 910 ng/mL (Fig 2) . AUCs differed by less than 10% in four of five cases from the values achieved after intravenous application.
In three dogs given oral busulfan tablets, the peak levels were 72, 120, and 720 ng/mL, respectively (Fig 2) . The corresponding AUC values were less than 20% of those achieved after intravenous application in two dogs and 99% in the third animal.
DISCUSSION
This study shows that busulfan dissolved in DMSO and further diluted in sodium chloride can safely be administered intravenously to dogs. It was of note that in contrast with the unpredictable absorption rate after oral administration of tablets, well documented clinically6-' and observed in the present study in at least two dogs, the oral administration of a busulfan solution (rather than in tablet form) resulted in a high and rather stable absorption rate and in plasma levels comparable with those observed with intravenous administration. This observation points toward a major role of physico-chemical problems of tablet dispersion and not to variations in drug uptake or extraction rate in the liver during first pass as causes of the high intrapatient and interpatient variability of oral busulfan. Another explanation of the higher absorption rate of the oral solution would be the involvement of lymphatic drainage bypassing the liver.
In a recent publication on the bioavailability of busulfan, Hassan et al" used intravenous bolus administration of busulfan dissolved in a solution containing propylene glycol, ethanol, and DMSO at a low dose of 0.2 mg/kg. In this study, the bioavailability of oral busulfan given as tablets ranged from 0.22 to 1.20 in children, and 0.47 to 1.03 in adults. With the intravenous preparation, given at doses of 0.2 mg/kg, AUC values clearly below levels desirable in clinical studies were reached. However, the authors pointed out that it was not advisable to administer this preparation at higher doses based on the poor stability of the preparation, low solubility and potential toxicity of bolus injections. The approach described here allows to circumvent the problems by using fresh preparations of the solution and by diluting it in sodium chloride to allow for a l-hour infusion. However, even bolus injections were well tolerated in dogs.
Dimethylbusulfan (DMB), a better soluble derivative of busulfan and more potent on a weight basis, had been used dissolved in DMSO as an intravenous preparation in earlier studies in animals14 and in clinical trials.".I6 The limited supply of DMB prevented a more extensive clinical evaluation and the drug is currently not available. Nevertheless it is of note that the administration of DMB in DMSO intravenously was not associated with prohibitive toxicity. Also DMSO is used successfully as cryoprotectant in BMTL"19 and has found other clinical uses in oncology and internal medicine,"22 not associated with unacceptable side effects.
On the basis of those data and the results obtained in the present study, it appears warranted to perform clinical trials using an intravenous preparation of busulfan. Such an approach is easier for the patient, assures high patient compliance and is likely to lead to more predictable blood levels and reduced toxicity of busulfan-containing regimens.
